Bendamustine 180 Mg/4 Ml Drl 180 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 21 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for specific leukemias and lymphomas.
Dosage (summary)
100 mg/mu00b2 on days 1 and 2 for CLL; 90 mg/mu00b2 for NHL with rituximab; 120-150 mg/mu00b2 for multiple myeloma.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP1A2 inhibitors
- Myelosuppressive agents
- Ciclosporin
- Tacrolimus
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Severe bone marrow suppression
- Pregnancy
- Lactation
Common side effects
- Leucopenia
- Thrombocytopenia
- Nausea
- Vomiting
- Rash
Counselling Points
- Monitor for signs of infection
- Avoid pregnancy
- Consider PJP prophylaxis if CD4 < 200
- Report severe skin reactions immediately
Serious warnings
- Myelosuppression
- Infections
- Hepatitis B reactivation
- Skin reactions
- Anaphylaxis
Important Disclaimer
The Bendamustine 180 Mg/4 Ml Drl 180 mg Concentrate for solution for infusion professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
